Research, Drug Development & ManufacturingLead program: Phase III

Reunion Neuroscience

Toronto, Ontario, Canada, Canada

4 Drug Candidates

Reunion Neuroscience is a private, Toronto-based clinical-stage biopharmaceutical company focused on short-duration, serotonergic psychedelic therapies for postpartum depression, adjustment disorder, and anxiety. Spun out of Field Trip Health in 2022, the company raised a $103M Series A in May 2024 (co-led by Novo Holdings and MPM BioImpact) and went private under CEO Greg Mayes. Its lead asset RE104 (luvesilocin) — a subcutaneous prodrug of 4-OH-DiPT, a psilocybin-like 5-HT2A agonist with shorter duration than psilocybin — met the primary endpoint of its RECONNECT Phase 2 trial for PPD (Aug 2025) and received FDA Breakthrough Therapy Designation on February 23, 2026. A single pivotal Phase 3 trial is planned for 2026.

Drug Pipeline

RE104 (luvesilocin)

Psilocybin

Phase III

Postpartum Depression

Postpartum depression (PPD). Subcutaneous prodrug of 4-OH-DiPT (psilocybin-like, short-acting). RECONNECT Phase 2 (n=84, 38 US sites): single 30mg SC dose met primary endpoint — -23.0 MADRS at Day 7 vs -17.2 for 1.5mg active control (p=0.0094); 71.4% remission vs 41.0%. Full data presented at ACNP Annual Meeting Jan 2026. FDA Breakthrough Therapy Designation granted Feb 23, 2026. Single pivotal Phase 3 trial planned 2026. End-of-Phase-2 FDA meeting completed.